NO20003514L - Hypolipidemiske benzothiazepin-forbindelser - Google Patents

Hypolipidemiske benzothiazepin-forbindelser

Info

Publication number
NO20003514L
NO20003514L NO20003514A NO20003514A NO20003514L NO 20003514 L NO20003514 L NO 20003514L NO 20003514 A NO20003514 A NO 20003514A NO 20003514 A NO20003514 A NO 20003514A NO 20003514 L NO20003514 L NO 20003514L
Authority
NO
Norway
Prior art keywords
benzothiazepine compounds
hypolipidemic benzothiazepine
compounds
hypolipidemic
solvates
Prior art date
Application number
NO20003514A
Other languages
English (en)
Other versions
NO20003514D0 (no
Inventor
Anthony Louis Handlon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20003514D0 publication Critical patent/NO20003514D0/no
Publication of NO20003514L publication Critical patent/NO20003514L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Det er beskrevet nye hypolipidemiske forbindelser ifølge formel (I), hvori R1 er H eller metyl og salter, solvater eller fysiologiske funksjonelle derivater derav, frem- gangsmåter og nye mellomprodukter for fremstilling derav, farmasøytiske sammen- setninger som inneholder disse og anvendelse i medisin, spesielt ved profylakse og behandling av hyperlipidemiske tilstander og assosierte sykdommer, så som athero- sklerose.
NO20003514A 1998-01-10 2000-07-07 Hypolipidemiske benzothiazepin-forbindelser NO20003514L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9800428.6A GB9800428D0 (en) 1998-01-10 1998-01-10 Chemical compounds
PCT/EP1999/000021 WO1999035135A1 (en) 1998-01-10 1999-01-07 Hypolipidemic benzothiazepine compounds

Publications (2)

Publication Number Publication Date
NO20003514D0 NO20003514D0 (no) 2000-07-07
NO20003514L true NO20003514L (no) 2000-09-07

Family

ID=10825042

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003514A NO20003514L (no) 1998-01-10 2000-07-07 Hypolipidemiske benzothiazepin-forbindelser

Country Status (27)

Country Link
US (1) US6465451B1 (no)
EP (1) EP1045840A1 (no)
JP (1) JP2002500220A (no)
KR (1) KR20010033988A (no)
CN (1) CN1292785A (no)
AP (1) AP2000001860A0 (no)
AR (1) AR014261A1 (no)
AU (1) AU2515599A (no)
BR (1) BR9906799A (no)
CA (1) CA2317651A1 (no)
CO (1) CO4820391A1 (no)
EA (1) EA200000623A1 (no)
GB (1) GB9800428D0 (no)
HR (1) HRP20000468A2 (no)
HU (1) HUP0201343A3 (no)
ID (1) ID25495A (no)
IL (1) IL137040A0 (no)
IS (1) IS5551A (no)
MA (1) MA26595A1 (no)
NO (1) NO20003514L (no)
NZ (1) NZ505453A (no)
PE (1) PE20000179A1 (no)
PL (1) PL341672A1 (no)
SK (1) SK10242000A3 (no)
TR (1) TR200001816T2 (no)
WO (1) WO1999035135A1 (no)
ZA (1) ZA9981B (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
MXPA01006472A (es) * 1998-12-23 2004-03-10 Searle Llc Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares.
DK1140184T3 (da) 1998-12-23 2003-09-29 Searle Llc Kombinationer af cholesterylestertransferproteinhæmmere og nikotinsyrederivater til hjertekar indikationer
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US20020183307A1 (en) * 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SE0003766D0 (sv) * 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) * 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) * 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
PL216023B1 (pl) 2001-09-08 2014-02-28 Astrazeneca Ab Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny
AU2003207431A1 (en) 2002-01-17 2003-09-02 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
FR2849024B1 (fr) * 2002-12-20 2007-11-02 Aventis Pharma Sa Nouveaux composes chiraux derives d'esters de l'acide hexanoique, procede et intermediaires de preparation, utilisation a la synthese de l'acide 2-(bromomethyl)2-ethyl hexanoique chiral
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
EP2367554A4 (en) * 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid reflux inhibitor for the treatment of obesity and diabetes
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
ES2586931T3 (es) 2010-11-04 2016-10-19 Albireo Ab Inhibidores de IBAT para el tratamiento de enfermedades hepáticas
RU2619215C2 (ru) 2010-11-08 2017-05-12 Альбирео Аб Фармацевтическая комбинация, включающая ibat-ингибитор и связующее желчной кислоты
KR102051031B1 (ko) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
EP2968230A2 (en) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
KR20160003664A (ko) 2013-03-15 2016-01-11 루메나 파마수티컬즈, 인코포레이티드 바렛 식도 및 위식도 역류 질환 치료용 담즙산 재순환 억제제
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
EP3413878B1 (en) 2016-02-09 2021-04-14 Albireo AB Oral cholestyramine formulation and use thereof
EP3413875B1 (en) 2016-02-09 2020-01-29 Albireo AB Cholestyramine pellets and methods for preparation thereof
EP3413877B1 (en) 2016-02-09 2021-04-07 Albireo AB Oral cholestyramine formulation and use thereof
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
CN110996915B (zh) 2017-08-09 2023-10-03 阿尔比里奥公司 考来烯胺丸粒、口服考来烯胺制剂及其用途
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
MX2020013839A (es) 2018-06-20 2021-03-25 Albireo Ab Formulacion farmaceutica de odevixibat.
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
RS63899B1 (sr) 2019-02-06 2023-02-28 Albireo Ab Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina
TWI835997B (zh) 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
CA3129826A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Methods for treating cholestasis
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
JP7665621B2 (ja) * 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4069359B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
JP7665620B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
TWI867107B (zh) 2019-12-04 2024-12-21 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
BR112022010505A2 (pt) 2019-12-04 2022-09-06 Albireo Ab Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
AR120682A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021390172A1 (en) 2020-12-04 2023-06-22 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CN119343140A (zh) 2022-06-09 2025-01-21 阿尔比里奥公司 治疗肝炎
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004534A1 (en) 1993-08-06 1995-02-16 Smithkline Beecham Corporation Endothelin receptor antagonists
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
GB9423172D0 (en) * 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines

Also Published As

Publication number Publication date
ID25495A (id) 2000-10-05
HUP0201343A3 (en) 2003-08-28
MA26595A1 (fr) 2004-12-20
CN1292785A (zh) 2001-04-25
GB9800428D0 (en) 1998-03-04
EA200000623A1 (ru) 2001-04-23
ZA9981B (en) 2000-07-06
WO1999035135A1 (en) 1999-07-15
IS5551A (is) 2000-06-27
EP1045840A1 (en) 2000-10-25
NZ505453A (en) 2002-11-26
SK10242000A3 (sk) 2001-02-12
JP2002500220A (ja) 2002-01-08
CO4820391A1 (es) 1999-07-28
AR014261A1 (es) 2001-02-07
NO20003514D0 (no) 2000-07-07
CA2317651A1 (en) 1999-07-15
US6465451B1 (en) 2002-10-15
AU2515599A (en) 1999-07-26
HUP0201343A2 (hu) 2003-06-28
PE20000179A1 (es) 2000-03-16
PL341672A1 (en) 2001-04-23
AP2000001860A0 (en) 2000-09-30
BR9906799A (pt) 2000-10-10
IL137040A0 (en) 2001-06-14
KR20010033988A (ko) 2001-04-25
HRP20000468A2 (en) 2000-10-31
TR200001816T2 (tr) 2000-11-21

Similar Documents

Publication Publication Date Title
NZ505453A (en) Hypolipidemic benzothiazepine compounds
DE69515183D1 (de) Hypolipidämische benzothiazepine
MY107740A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
MY132473A (en) Crystalline hydrochloride of (r)-(-)-2-<n-[4-(1,1- dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl>-chroman
NO960393L (no) Heterosykliske fenylforbindelser som COX-2-inhibitorer
NO20041041L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
WO2004026863A8 (en) Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
AU2267395A (en) Benzofuran derivatives useful as inhibitors of bone resorption
PT1213296E (pt) Derivados de glucopiranosiloxipirazole composicoes medicas que os contem e intermediarios na sua producao
WO1997030677A3 (en) Pentafluorobenzenesulfonamides and analogs
MY141773A (en) (methylsulfonyl)phenyl-2-(5h)-furanones as cox-2 inhibitors
BR9711135A (pt) Composto composi-Æo farmac-utica utiliza-Æo de um composto e processos para prepara-Æo de um composto e para inibi-Æo de Äxido-equaleno ciclase num animal de sangue quente requerendo um tal tratamento
NO302474B1 (no) Sakarinderivater, farmasöytisk sammensetning og anvendelse derav
YU16899A (sh) Aralkil i aralkiliden heterociklicni laktami i imidi
IL104154A0 (en) Saccharin derivatives,their preparation and pharmaceutical compositions containing them
DK0874812T3 (da) Hidtil ukendte 2,3,5-trimethyl-4-hydroxyanilidderivater, fremstilling deraf og terapeutisk anvendelse deraf
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
PT992509E (pt) Novos derivados macrolidos
SE9804212D0 (sv) Compounds
NO308654B1 (no) Amid-derivater, fremgangsmÕter og mellomprodukter for fremstilling derav, deres anvendelse og farmasøytiske blandinger som inneholdende dem
FI873892A0 (fi) Nya derivat av dihydro-oxazol, foerfarande foer deras framstaellning och deras anvaendning.
ZA903111B (en) 2-hydroxy-3-phenoxypropylamino compounds and pharmaceutical compositions containing them
NO985974L (no) Piperidineddiksyrederivater og deres anvendelse ved behandling av trombose-sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application